MedPath

The BASA Study: Breath Analysis for Severe Asthma Patients

Recruiting
Conditions
Severe Asthma
Registration Number
NCT05946421
Lead Sponsor
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Brief Summary

This study will evaluate the fluctuations of exhaled breath markers in patients with severe asthma on biologics. In the study, severe asthma patients will be followed up to 16 weeks monitoring lung function and inflammation through non-invasive technologies such as exhaled breath analysis (FeNO, GC-MS and EBC). A control group will be followed up to two weeks with the overall objective to indentify and evaluate the modifcations of markers of inflammation in patient under biologic treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Severe asthma diagnosis according to the latest recommendation
  • Eligible or in treatment with a biologic treatment for severe asthma
  • Able to follow istructions
  • Able and willing to sign the informed consent
Exclusion Criteria
  • Not able to perform lung function measurements and the procedures of the study
  • Acute respiratory or non respiratory infection (<4 weeks)
  • Not willing to continue the study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
evaluate the fluctuations of markers of inflammation in patients with severe asthma under biologic therapy16 weeks
Secondary Outcome Measures
NameTimeMethod
evaluate whether the measurement of H2O2 could be considered as a marker of inflammation in severe asthma patients16 weeks

Trial Locations

Locations (1)

AOUP Policlinico Paolo Giaccone

🇮🇹

Palermo, Italy

AOUP Policlinico Paolo Giaccone
🇮🇹Palermo, Italy
Carmen Durante
Sub Investigator
Nicola Scichilone, Prof
Principal Investigator
Stefania Principe, PhD
Principal Investigator
Alida Benfante, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.